ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT)

96 filings reported holding ADCT - ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share as of Q4 2024.
ADC Therapeutics SA - Common Shares, par value CHF 0.08 per share (ADCT) has 81 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 56.5M shares of 112M outstanding shares and own 50.47% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (15.7M shares), Prosight Management, LP (9.52M shares), ORBIMED ADVISORS LLC (5.97M shares), BlackRock, Inc. (5.01M shares), MORGAN STANLEY (3.96M shares), Woodline Partners LP (1.93M shares), GOLDMAN SACHS GROUP INC (1.67M shares), PLATINUM INVESTMENT MANAGEMENT LTD (1.61M shares), BANK OF AMERICA CORP /DE/ (1.29M shares), and STATE STREET CORP (1.19M shares).
This table shows the top 81 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.